Somnus Announces the Availability of a New Device for the Turbinate Somnoplasty(R) Treatment

Redesigned Turbinate Handpiece Ergonomic and Easy to Use



Apr 03, 2001, 01:00 ET from Somnus Medical Technologies, Inc.

    SUNNYVALE, Calif., April 3 /PRNewswire/ --
 Somnus Medical Technologies, Inc. (Nasdaq:   SOMN), announced today it has begun
 customer shipment of a new Turbinate Somnoplasty Device for the treatment of
 chronic nasal obstruction, or a stuffy nose, due to enlarged turbinates.  The
 U.S. Food and Drug Administration (FDA) cleared the initial Turbinate
 Somnoplasty Device in 1997.
     The ergonomic design of the new turbinate handpiece allows for easy
 electrode placement.  Its design provides physicians with the ability to reach
 all areas of the inferior turbinate.  Its streamlined design allows for
 enhanced visualization.
     "Physicians who have evaluated the new handpiece felt it enhanced their
 ability to effectively treat patients with chronically enlarged turbinates.
 It continues to provide the same excellent results-improved breathing and
 longer lasting relief from chronic nasal congestion," said John Schulte,
 Somnus President and Chief Executive Officer.
     Enlarged turbinates and nasal congestion can impair normal breathing,
 force patients to breathe through the mouth and turn the simple acts of
 eating, drinking, and speaking into an annoying and sometimes painful
 experience.  A chronic stuffy nose can also contribute to headaches and sleep
 disorders such as snoring and obstructive sleep apnea, as the nasal airway is
 the normal breathing route during sleep.
     Those suffering from enlarged turbinates often endure the prolonged use of
 intranasal sprays and medication -- some carrying significant side effects.
 Over time, compliance and effectiveness of these medical therapies can be
 compromised.  Historically, surgical intervention was the only permanent
 solution considered for only the most severely affected patients.
     The Turbinate Somnoplasty Treatment is performed in an outpatient setting
 under local anesthesia.  It takes less than two minutes per turbinate and
 avoids the pain and inconvenience associated with traditional techniques.
 Patients enjoy a speedy recovery and may avoid the long-term use of
 medications and nasal sprays.
 
     About the Somnoplasty System and Its Applications
     Somnus is pioneering a new standard of care for the treatment of upper
 airway disorders.  The Company's proprietary Somnoplasty System is the only
 temperature-controlled radiofrequency-based technology that has been
 previously cleared by the FDA for use in the treatment of chronic nasal
 obstruction and sleep disordered breathing-obstructive sleep apnea syndrome,
 upper airway resistance syndrome, habitual snoring, as well as a device for
 tissue coagulation in the head and neck.  The Somnoplasty procedures work by
 heating a targeted area of obstructive tissue below the surface.  The body
 naturally resorbs the heated area over a period of three to eight weeks
 reducing tissue volume.  Clinical evaluations are underway to further expand
 the indications for the treatment of other upper airway obstructions.
     Somnus is headquartered in Sunnyvale, Calif.  More information about
 Somnus and the Somnoplasty Procedure may be found at http://www.somnus.com and
 http://www.somnoplasty.com/ , respectively.
     NOTE:  Somnus, Somnoplasty and the Somnus Medical Technologies logo are
 registered trademarks or service marks of Somnus Medical Technologies, Inc.
 
 

SOURCE Somnus Medical Technologies, Inc.
    SUNNYVALE, Calif., April 3 /PRNewswire/ --
 Somnus Medical Technologies, Inc. (Nasdaq:   SOMN), announced today it has begun
 customer shipment of a new Turbinate Somnoplasty Device for the treatment of
 chronic nasal obstruction, or a stuffy nose, due to enlarged turbinates.  The
 U.S. Food and Drug Administration (FDA) cleared the initial Turbinate
 Somnoplasty Device in 1997.
     The ergonomic design of the new turbinate handpiece allows for easy
 electrode placement.  Its design provides physicians with the ability to reach
 all areas of the inferior turbinate.  Its streamlined design allows for
 enhanced visualization.
     "Physicians who have evaluated the new handpiece felt it enhanced their
 ability to effectively treat patients with chronically enlarged turbinates.
 It continues to provide the same excellent results-improved breathing and
 longer lasting relief from chronic nasal congestion," said John Schulte,
 Somnus President and Chief Executive Officer.
     Enlarged turbinates and nasal congestion can impair normal breathing,
 force patients to breathe through the mouth and turn the simple acts of
 eating, drinking, and speaking into an annoying and sometimes painful
 experience.  A chronic stuffy nose can also contribute to headaches and sleep
 disorders such as snoring and obstructive sleep apnea, as the nasal airway is
 the normal breathing route during sleep.
     Those suffering from enlarged turbinates often endure the prolonged use of
 intranasal sprays and medication -- some carrying significant side effects.
 Over time, compliance and effectiveness of these medical therapies can be
 compromised.  Historically, surgical intervention was the only permanent
 solution considered for only the most severely affected patients.
     The Turbinate Somnoplasty Treatment is performed in an outpatient setting
 under local anesthesia.  It takes less than two minutes per turbinate and
 avoids the pain and inconvenience associated with traditional techniques.
 Patients enjoy a speedy recovery and may avoid the long-term use of
 medications and nasal sprays.
 
     About the Somnoplasty System and Its Applications
     Somnus is pioneering a new standard of care for the treatment of upper
 airway disorders.  The Company's proprietary Somnoplasty System is the only
 temperature-controlled radiofrequency-based technology that has been
 previously cleared by the FDA for use in the treatment of chronic nasal
 obstruction and sleep disordered breathing-obstructive sleep apnea syndrome,
 upper airway resistance syndrome, habitual snoring, as well as a device for
 tissue coagulation in the head and neck.  The Somnoplasty procedures work by
 heating a targeted area of obstructive tissue below the surface.  The body
 naturally resorbs the heated area over a period of three to eight weeks
 reducing tissue volume.  Clinical evaluations are underway to further expand
 the indications for the treatment of other upper airway obstructions.
     Somnus is headquartered in Sunnyvale, Calif.  More information about
 Somnus and the Somnoplasty Procedure may be found at http://www.somnus.com and
 http://www.somnoplasty.com/ , respectively.
     NOTE:  Somnus, Somnoplasty and the Somnus Medical Technologies logo are
 registered trademarks or service marks of Somnus Medical Technologies, Inc.
 
 SOURCE  Somnus Medical Technologies, Inc.

RELATED LINKS

http://www.somnus.com